pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
CRISPR/Cas9 · news · pharmadog
← back to CRISPR/Cas9
News · CRISPR/Cas9
99
stories
19d
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
24d
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
biospace
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
25d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
25d
Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil
endpoints
28d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
28d
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
stat
28d
Michael Ehlers joins Formation Bio to lead R&D; Black Diamond co-founder dies at 67
endpoints
29d
Gene editor Scribe starts second-half IPO spree with $129M listing
endpoints
29d
Scribe secures $129M in a rare gene editing IPO
biopharma dive
29d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 22, 26
6 companies hiring in Cambridge now
biospace
Jul 20, 26
Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
endpoints
Jul 20, 26
Genetic medicine luminaries launch new center for personalized therapies
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 17, 26
STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
stat
Jul 15, 26
Nobel Laureate Jennifer Doudna enters AI protein design arena
fiercebiotech
Jul 13, 26
STAT+: Dementia study replicates promising outcomes following risk-reduction strategies
stat
Jul 13, 26
STAT+: All eyes on data on Biogen’s tau therapy
stat
Jul 13, 26
STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come
stat
Jul 12, 26
STAT+: Tau in the spotlight at Alzheimer’s conference
stat
Jul 10, 26
STAT+: Roche ends Huntington’s gene-silencing programs
stat
Jul 10, 26
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
biopharma dive
Jul 10, 26
FDA quietly pushes back deadline on electric shock ban
stat
Jul 10, 26
New York boys club has a time-tested recipe to protect members’ mental health
stat
Jul 9, 26
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
endpoints
Jul 9, 26
Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
stat
Jul 9, 26
STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
stat
Jul 8, 26
Prime Medicine wins spat with Beam Therapeutics over AATD candidate
endpoints
Jul 8, 26
STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
stat
← prev
page 2 of 4
next →
